Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Lung cancer immunotherapy.

Luis E Raez1, Steven Fein, Eckhard R Podack

  • 1Epidemiology and Public Health, Sylvester Comprehensive Cancer Center, University of Miami School of Medicine, FL 33136, USA. lraez@med.miami.edu

Clinical Medicine & Research
|November 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HER2 Therapies in Non-Small Cell Lung Cancer (NSCLC).

International journal of molecular sciences·2026
Same author

Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.

JAMA·2026
Same author

Ready, Set, Screen: Evaluating Community Readiness for Lung Cancer Screening Among Non-Hispanic Black Populations in Florida: Brief Report.

JTO clinical and research reports·2026
Same author

The association between first trimester iron deficiency without anemia and the development of iron-deficiency anemia prior to childbirth.

American journal of obstetrics and gynecology·2026
Same author

Corrigendum to "Clinical and economic impact of the availability of innovative therapies for advanced lung cancer in men in Latin America: a population-based secondary data study"- the Lancet Regional Health-Americas 2025; Volume 49: 101172; DOI: 10.1016/j.lana.2025.101172.

Lancet regional health. Americas·2025
Same author

The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast.

Oncology and therapy·2025

Recent advances in anti-tumor immunotherapy are driving new lung cancer treatments. More specific vaccines are being developed to target tumor antigens, improving immune responses for future lung cancer therapy.

Area of Science:

  • Oncology
  • Immunology

Background:

  • Anti-tumor immunotherapy is a rapidly advancing field with significant implications for cancer treatment.
  • Lung cancer immunotherapy has seen a surge in clinical trials, reflecting its growing importance.

Purpose of the Study:

  • To review the evolution of immunotherapy strategies for lung cancer.
  • To highlight the importance of understanding anti-tumor immunity mechanisms and target antigens.

Main Methods:

  • Review of recent insights and clinical trials in lung cancer immunotherapy.
  • Discussion of vaccine development from nonspecific to specific strategies.

Main Results:

  • Immunotherapy, particularly specific vaccines, shows promise in generating active immune responses against tumor-associated antigens.

Related Experiment Videos

  • Understanding immune mechanisms is key to improving current and future lung cancer therapies.

    • Conclusions:

    • Specific and potent immunotherapy strategies are emerging as a promising avenue for lung cancer treatment.
    • Further research into anti-tumor immunity and antigen identification will refine these therapeutic approaches for lung cancer.